NSCLC patients can develop resistance to EGFR-TKIs through EGFR-independent mechanisms, such as activation of alternative bypass pathways, aberrant downstream signaling, or histologic transformation[5,31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.